Combo Products User Fee Final Guidance Reflects Industry Comments
This article was originally published in The Gray Sheet
Executive Summary
A FDL-1final guidance released April 21 by FDA's Office of Combination Products assures industry stakeholders that user fee waivers are attainable if a firm decides to submit two applications instead of one